2022
DOI: 10.1016/j.ejso.2021.12.412
|View full text |Cite
|
Sign up to set email alerts
|

‘Cost-effectiveness of the three EMA-approved adjuvant systemic therapies in patients with high-risk melanoma: a model-based economic evaluation’

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles